Mayne Pharma Group Limited in brief
Mayne Pharma Group Limited is a listed company in the Pharmaceutical industry, based in Australia. It was founded in 1845. Its last known market value was $330 M (January 2024); there is no current figure. Its shares trade under the symbol MYX.AX (ASX).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd is an ASX listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals. The company annual revenue is 400.3 million EUR, annual operating income is 21.3 million EUR and total assets are 1,463 million EUR as on 2021. The headquarters is in Australia.
Mayne Pharma Group Limited timeline
- 1845
- 🏁· approximateFounded
- 2007
- 🔔Initial public offering on Australian Securities Exchange as MYX
Events of Mayne Pharma Group Limited from Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Australia: #344 (Jan 2022) · #372 (Dec 2022) · #340 (Jul 2023) · #298 (Jan 2024)
Mutual funds holding Mayne Pharma Group Limited#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc. | 1.04 M | $2 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Developed Markets Index FundThe Vanguard Group, Inc. | 794,498 | $2 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP | 280,148 | $1 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 The Asia Pacific Small Company SeriesDimensional Fund Advisors LP | 228,283 | $0 M | — | 0.02% | −24% | Jul 31, 2026 |
| 🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc. | 208,615 | $0 M | — | <0.01% | −41% | Jul 31, 2026 |
| 🇺🇸 Avantis International Small Cap Value ETFAmerican Century ETF Trust | 147,610 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Vanguard Pacific Stock Index FundThe Vanguard Group, Inc. | 101,822 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP | 90,536 | $0 M | — | <0.01% | −11% | Jul 31, 2026 |
| 🇺🇸 iShares International Small-Cap Equity Factor ETFBlackRock Fund Advisors | 62,178 | $0 M | — | 0.02% | +2.1% | Jul 31, 2026 |
| 🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP | 61,400 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc. | 53,582 | $0 M | — | 0.01% | +1.0% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc. | 45,285 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Old Westbury Small & Mid Cap Strategies FundBessemer Investment Management LLC | 42,819 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dfa International Small Cap Value PortfolioDimensional Fund Advisors LP | 41,255 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Avantis International Equity ETFAmerican Century ETF Trust | 42,015 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP | 17,302 | $0 M | — | <0.01% | −45% | Jul 31, 2026 |
| 🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC | 15,480 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 International Vector Equity PortfolioDimensional Fund Advisors LP | 14,630 | $0 M | — | <0.01% | −51% | Jul 31, 2026 |
| 🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP | 14,501 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc. | 11,925 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 LVIP Dimensional International Core Equity FundLincoln Financial Investments Corporation | 10,321 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis Responsible International Equity ETFAmerican Century ETF Trust | 7,666 | $0 M | — | <0.01% | +0.9% | May 31, 2026 |
| 🇺🇸 International Small Company TrustJohn Hancock Variable Trust Advisers LLC | 4,957 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis International Small Cap Equity ETFAmerican Century ETF Trust | 5,498 | $0 M | — | <0.01% | +18% | May 31, 2026 |
| 🇺🇸 AZL DFA International Core Equity FundAllianz Investment Management LLC | 4,918 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Avantis International Equity FundAmerican Century ETF Trust | 2,120 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional International Vector Equity ETFDimensional Fund Advisors LP | 907 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 27 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
FDA drug approvals: Mayne Pharma Group Limited#
16 approved applications held, 3 of them new molecular entities; 1 approvals and 0 new uses in 2022.
| Approved | Drug | Kind |
|---|---|---|
| 2022-04-22 | EpsolayBenzoyl Peroxide · NDA214510 | New drug (NDA) |
| 2021-12-28 | Bijuvanew useEstradiol, Progesterone · NDA210132 (SUPPL-6) | New drug (NDA) |
| 2021-08-18 | Lexettenew useHalobetasol Propionate · NDA210566 (SUPPL-3) | New drug (NDA) |
| 2021-07-26 | TwyneoBenzoyl Peroxide, Tretinoin · NDA214902 | New drug (NDA) |
| 2021-04-15 | Nextstellisnew moleculeDrospirenone, Estetrol · NDA214154 | New drug (NDA) |
| 2019-11-05 | Soriluxnew useCalcipotriene · NDA022563 (SUPPL-7) | New drug (NDA) |
| 2019-05-06 | Soriluxnew useCalcipotriene · NDA022563 (SUPPL-6) | New drug (NDA) |
| 2018-12-11 | TolsuraItraconazole · NDA208901 | New drug (NDA) |
| 2018-10-28 | BijuvaEstradiol, Progesterone · NDA210132 | New drug (NDA) |
| 2018-08-10 | Annoveranew moleculeEthinyl Estradiol, Segesterone Acetate · NDA209627 | New drug (NDA) |
| 2018-05-29 | ImvexxyEstradiol · NDA208564 | New drug (NDA) |
| 2018-05-24 | LexetteHalobetasol Propionate · NDA210566 | New drug (NDA) |
| 2017-05-31 | Doryx Mpc, Doryxnew useDoxycycline Hyclate · NDA050795 (SUPPL-24) | New drug (NDA) |
| 2017-01-18 | Rhofadenew moleculeOxymetazoline Hydrochloride · NDA208552 | New drug (NDA) |
| 2016-05-20 | Doryx Mpc, Doryxnew useDoxycycline Hyclate · NDA050795 (SUPPL-22) | New drug (NDA) |
| 2015-11-17 | Hydrocodone Bitartrate And Pseudoephedrine HydrochlorideHydrocodone Bitartrate, Pseudoephedrine Hydrochloride · ANDA205658 | Generic drug (ANDA) |
| 2015-08-03 | Hydrocodone Bitartrate, Chlorpheniramine Maleate And Pseudoephedrine HydrochlorideChlorpheniramine Maleate, Hydrocodone Bitartrate, Pseudoephedrine Hydrochloride · ANDA205657 | Generic drug (ANDA) |
| 2013-04-11 | Doryx Mpc, Doryxnew useDoxycycline Hyclate · NDA050795 (SUPPL-10) | New drug (NDA) |
| 2012-09-27 | Soriluxnew useCalcipotriene · NDA022563 (SUPPL-2) | New drug (NDA) |
| 2012-05-11 | FabiorTazarotene · NDA202428 | New drug (NDA) |
| 2010-10-06 | SoriluxCalcipotriene · NDA022563 | New drug (NDA) |
| 2007-08-20 | Fentanyl-75, Fentanyl-25, Fentanyl-100, Fentanyl-50Fentanyl · ANDA077062 | Generic drug (ANDA) |
| 2006-12-19 | Doryx Mpc, Doryxnew useDoxycycline Hyclate · NDA050795 (SUPPL-2) | New drug (NDA) |
| 2005-05-06 | Doryx Mpc, DoryxDoxycycline Hyclate · NDA050795 | New drug (NDA) |
| 1985-07-22 | DoryxDoxycycline Hyclate · NDA050582 | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (MAYNE PHARMA), so they follow acquisitions
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Mayne Pharma Group Limited🇦🇺 | $330 M | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Profile updated:
- Nov 15, 2026
Figures from Wikidata, value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Mayne Pharma Group Limited? Verify and update this profile — free
Show Mayne Pharma Group Limited's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.